phase clinic pharmacolog studi intraperiton cisplatin fluorouracil patient advanc intraabdomin cancer fluorouracil cisplatin display therapeut synergi preclin model effect treatment number solid tumor IV drug IP favor pharmacolog profil accept clinic toxic phase feasibl toxic combin IP chemotherapi agent patient malign periton space cisplatin mix lactat ringer solut IP hour day cohort patient concentr mmol/l mg mmol/l dose-limit toxic median granulocyt nadir cell microlit dose mmol/l intrapati escal dose cycl chemotherapi concentr mmol/l concentr mmol/l other toxic mild nausea cycl therapi cycl diarrhea cycl abdomin pain renal dysfunct peripher neuropathi oral mucos dose periton fluid plasma concentr high-perform liquid chromatographi hplc patient mean peak plasma concentr mumol/l mumol/l periton fluid area curv auc ratio nine patient nonbulki diseas resolut malign ascit reduct periton stud tumor repeat laparotomi combin IP chemotherapi cisplatin feasibl accept clinic toxic favor pharmacolog profil recommend dose phase II trial mg mix cisplatin isoton fluid 